Alibaba
BABA
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
Apple
AAPL
US Stock MarketDetailed Quotes
STTK Shattuck Labs
- 1.330
- +0.080+6.40%
Close Feb 14 16:00 ET
- 1.370
- +0.040+3.01%
Post 19:16 ET
63.49MMarket Cap-0.87P/E (TTM)
1.360High1.240Low132.77KVolume1.260Open1.250Pre Close173.86KTurnover0.49%Turnover RatioLossP/E (Static)47.74MShares11.76052wk High0.66P/B36.27MFloat Cap0.94052wk Low--Dividend TTM27.27MShs Float60.516Historical High--Div YieldTTM9.60%Amplitude0.940Historical Low1.309Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Shattuck Labs Stock Forum
Abstract accepted for poster presentation at the upcoming Crohn's and Colitis Congress, to be held February 6–8, 2025 in San Francisco, CA.Abstract accepted for oral presentation at the upcoming20th European Crohn's and Colitis Organization Congress, to be held February 19–22, 2025 in Berlin, Germany.
Upcoming Investor Conference Pre...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
No comment yet